Literature DB >> 19411764

The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus.

Michael P Cancro1, David P D'Cruz, Munther A Khamashta.   

Abstract

SLE, a chronic, multisystem autoimmune disorder with a broad range of symptoms, involves defective B cell selection and elimination of self-reactive B cells. B lymphocyte stimulator (BLyS), a soluble ligand of the TNF cytokine family, is a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. High levels of BLyS may relax B cell selection and contribute to autoantibody production, exacerbating the SLE disease state. This review discusses the mechanism of BLyS action on B cells, its role in SLE, and specific targeting of BLyS in the treatment of SLE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19411764      PMCID: PMC2673851          DOI: 10.1172/JCI38010

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  104 in total

Review 1.  The multifaceted roles of TRAFs in the regulation of B-cell function.

Authors:  Gail A Bishop
Journal:  Nat Rev Immunol       Date:  2004-10       Impact factor: 53.106

2.  Clonal deletion of autoreactive B lymphocytes in bone marrow chimeras.

Authors:  D Nemazee; K Buerki
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

3.  The association of HLA-linked genes with systemic lupus erythematosus.

Authors:  J R Green; M Montasser; J C Woodrow
Journal:  Ann Hum Genet       Date:  1986-01       Impact factor: 1.670

4.  Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice.

Authors:  C C Goodnow; J Crosbie; S Adelstein; T B Lavoie; S J Smith-Gill; R A Brink; H Pritchard-Briscoe; J S Wotherspoon; R H Loblay; K Raphael
Journal:  Nature       Date:  1988-08-25       Impact factor: 49.962

5.  B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.

Authors:  R John Looney; Jennifer H Anolik; Debbie Campbell; Raymond E Felgar; Faith Young; Lois J Arend; James A Sloand; Joseph Rosenblatt; Iñaki Sanz
Journal:  Arthritis Rheum       Date:  2004-08

6.  Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome.

Authors:  Anne J Novak; Deanna M Grote; Mary Stenson; Steven C Ziesmer; Thomas E Witzig; Thomas M Habermann; Brandon Harder; Kay M Ristow; Richard J Bram; Diane F Jelinek; Jane A Gross; Stephen M Ansell
Journal:  Blood       Date:  2004-07-13       Impact factor: 22.113

7.  Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus.

Authors:  Meera Ramanujam; Xiaobo Wang; Weiqing Huang; Lena Schiffer; Christine Grimaldi; Alla Akkerman; Betty Diamond; Michael P Madaio; Anne Davidson
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

Review 8.  Cardiovascular manifestations of systemic lupus erythematosus.

Authors:  N E Doherty; R J Siegel
Journal:  Am Heart J       Date:  1985-12       Impact factor: 4.749

9.  Evidence for the clonal abortion theory of B-lymphocyte tolerance.

Authors:  G J Nossal; B L Pike
Journal:  J Exp Med       Date:  1975-04-01       Impact factor: 14.307

10.  Receptor editing: an approach by autoreactive B cells to escape tolerance.

Authors:  D Gay; T Saunders; S Camper; M Weigert
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

View more
  81 in total

Review 1.  Fibrosis: ultimate and proximate causes.

Authors:  Victor J Thannickal; Yong Zhou; Amit Gaggar; Steven R Duncan
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

Review 2.  Belimumab: in systemic lupus erythematosus.

Authors:  Celeste B Burness; Paul L McCormack
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

Review 3.  Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies.

Authors:  A Vossenkämper; P M K Lutalo; J Spencer
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

4.  B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels.

Authors:  Lauren L Ritterhouse; Sherry R Crowe; Timothy B Niewold; Joan T Merrill; Virginia C Roberts; Amy B Dedeke; Barbara R Neas; Linda F Thompson; Joel M Guthridge; Judith A James
Journal:  Arthritis Rheum       Date:  2011-12

5.  IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.

Authors:  Johan Nilvebrant; D Cameron Dunlop; Aroop Sircar; Thierry Wurch; Emilia Falkowska; Janice M Reichert; Gustavo Helguera; Emily C Piccione; Simon Brack; Sven Berger
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

6.  The missing link between smoking and COPD autoreactivity?

Authors:  Steven R Duncan
Journal:  Am J Respir Crit Care Med       Date:  2011-10-01       Impact factor: 21.405

Review 7.  Targeted therapy for systemic sclerosis: how close are we?

Authors:  Manuel Ramos-Casals; Vicent Fonollosa-Pla; Pilar Brito-Zerón; Antoni Sisó-Almirall
Journal:  Nat Rev Rheumatol       Date:  2010-04-13       Impact factor: 20.543

8.  Markers of childhood lupus nephritis indicating disease activity.

Authors:  Monika Edelbauer; Sudhir Kshirsagar; Magdalena Riedl; Dieter Haffner; Heiko Billing; Burkhard Tönshoff; Sophia Ross; Jörg Dötsch; Oliver Amon; Henry Fehrenbach; Christian Steuber; Antje Beissert; Josef Hager; Gottfried Wechselberger; Lutz T Weber; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2010-12-22       Impact factor: 3.714

9.  Autoimmune-mediated glucose intolerance in a mouse model of systemic lupus erythematosus.

Authors:  Curtis L Gabriel; Patricia B Smith; Yanice V Mendez-Fernandez; Ashley J Wilhelm; Audrey Musi Ye; Amy S Major
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-10-02       Impact factor: 4.310

10.  Belimumab in systemic lupus erythematosus: an update for clinicians.

Authors:  Susan S Kim; Kyriakos A Kirou; Doruk Erkan
Journal:  Ther Adv Chronic Dis       Date:  2012-01       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.